Crane Co. (CR) Tops Q3 EPS by 2c, Updates FY Guidance
Get Alerts CR Hot Sheet
Price: $219.04 -1.74%
Financial Fact:
Net income before allocation to noncontrolling interests: 63.7M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Net income before allocation to noncontrolling interests: 63.7M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Crane Co. (NYSE: CR) reported Q3 EPS of $1.86, $0.02 better than the analyst estimate of $1.84. Revenue for the quarter came in at $815 million versus the consensus estimate of $816.58 million.
GUIDANCE:
Crane Co. sees FY2022 EPS of $7.58-$7.72, versus the consensus of $7.75.
- We are adjusting the midpoint of our full year 2022 GAAP EPS guidance primarily to reflect the third quarter after-tax charges of $2.83 per share related to the August asbestos entity sale transaction, and we are narrowing the range to $6.58-$6.72, from our prior range of $9.80-$10.20.
- We are reaffirming the midpoint of our adjusted EPS guidance, and narrowing the range to $7.58-$7.72, from our prior range of $7.45-$7.85.
- We expect 2022 adjusted free cash flow (cash provided by operating activities less capital spending, and less the cash outflows associated with the divestiture of asbestos-related assets and liabilities and other portfolio actions) of $350 million-$390 million, excluding approximately $615 million of cash flow items related to 2022 portfolio actions and the asbestos divestiture transaction. (Please see the attached non-GAAP Financial Measures tables.)
For earnings history and earnings-related data on Crane Co. (CR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
- KULR Technology Group (KULR) Misses Q2 EPS by 39c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share